Clinical Trial Update: A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma [Phase 2, Phase 3]

View source ↗

Summary

This clinical trial update describes a Phase II/III randomized study comparing TACE plus an oral triple-agent cocktail versus TACE plus first-line targeted immu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Hepatocellular Carcinoma | Phase 2, Phase 3 | Status: NOT_YET_RECRUITING